Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7569672 Antibodies that bind to EphA2 and methods of use thereof

Patent 7569672 was granted and assigned to Raven Biotechnologies on August, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Raven Biotechnologies

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jennie P. Mather0

Penelope E. Roberts0

Date of Patent

August 4, 2009

0

Patent Application Number

113493270

Date Filed

February 6, 2006

0

Patent Citations Received

US Patent 11685781 Variant CD3-binding domains and their use in combination therapies for the treatment of disease

0

US Patent 11942149 Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof

0

US Patent 11840571 Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4

0

US Patent 11697684 Tri-specific binding molecules that specifically bind to multiple cancer antigens

0

Patent Primary Examiner

Christopher H. Yaen

0

Patent abstract

Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7569672 Antibodies that bind to EphA2 and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool